Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRYZ-T101 for HPV18 Positive Solid Tumors
NCT05952947Phase 1Recruiting
- Sponsor
- HRYZ Biotech
- Start
- Nov 2023
- Primary completion
- Dec 2027
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRYZ-T101 in Cervical Cancer (CC), head and neck squamous cell carcinoma (HNSCC), vaginal carcinoma and 3 more, sponsored by HRYZ Biotech. Primary endpoints: Dose Limiting Toxicity at 28 days and Adverse Events and Serious Adverse Events at 2 years. Started Nov 2023; status: recruiting.
02
Drugs
HRYZ-T101
03
Conditions
Cervical Cancer (CC)head and neck squamous cell carcinoma (HNSCC)vaginal carcinomapenile carcinomaanal cancer
Beyond the preview
Go deeper on NCT05952947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05952947.